How prostate cancer may “infect” normal prostate cells

There is a constant stream of scientific papers that focus on the possible ways that prostate cancer may start to spread within the prostate and then elsewhere. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …

Patient satisfaction at 24 months after treatment for localized prostate cancer

The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. … READ MORE …

The post-treatment testosterone debate

Conventional wisdom (dating back to the 1940s) has long been that giving testosterone supplements to men who had been treated for prostate cancer is a really bad idea. … READ MORE …

Active surveillance at the EAU annual meeting

Active surveillance and its role in the management of lower-risk forms of prostate cancer, and related issues like MRI scanning, were clearly key topics of attention at the annual meeting of the European Association of Urology in Barcelona over the weekend. … READ MORE …

PREDICT Prostate: a new, sophisticated, prostate cancer prognostic tool

A new paper just published in PLOS Medicine describes the development of a new online tool called PREDICT Prostate. … READ MORE …

Prostvac in the treatment of prostate cancer: an update

As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. … READ MORE …

The Metastatic Prostate Cancer Project: an update

In May 2017 we first let you know about the start-up of the Metastatic Prostate Cancer Project, which was subsequently launched in January 2018. Prostate Cancer International is one of the founding partners — along with the Broad Institute and others — in the development and evolution of this project. … READ MORE …

Low-dose aspirin and prostate cancer-specific mortality

A newly published article — and an associated editorial — in the Annals of Internal Medicine has addressed the possible benefits of taking low-dose aspirin as a method to prevent the progression of newly diagnosed prostate cancer. … READ MORE …

Yes, you are at risk … but risk of exactly what?

An article just published in Urologic Oncology has reported — perhaps not surprisingly — that men who have a single, initial negative biopsy as a consequence of suspicion of prostate cancer are at significant risk for actual diagnosis of prostate cancer over the next 20 years. … READ MORE …

Talazoparib + enzalutamide in treatment of mCRPC

Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Cardiovascular history, abiraterone acetate, and 6-month mortality rates

In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …

LAST CHANCE to participate in our current survey

By late yesterday nearly 600 men had completed our recent survey and most of them had expressed some degree of interest in participating in the quality of life trial we will be initiating soon. Again, thanks to all of you who have done that. … READ MORE …

Do men on AS need their own support groups?

Howard Wolinsky is a long-time prostate cancer patient who has been on active surveillance (AS) since his diagnosis in 2010, when one of his doctors described him as a “poster child” for active surveillance. … READ MORE …

Modern prostate cancer imaging: application of the right scan at the right time

A new “opinion” article in the Journal of Clinical Oncology this week has addressed the complex issue of how best to think about (a) how we are regulating use of and (b) how we are applying new forms of imaging technique in the management of prostate cancer … READ MORE …